I-CARE, a European Prospective Cohort Study AssessingSafety and Effectiveness of Biologics in Inflammatory Bowel Disease
Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamás Molnar, Mark Löwenberg, Jonas Halfvarson, Edyta Zagorowicz, Hélène Rousseau, Cédric Baumann, Filip Baert, and Laurent Beaugerie, for the I-CARE
Collaborator Group
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study
Aurelien Amiot, Jean-Francois Rahier, Filip Baert, Stephane Nahon, Ailsa Hart, Nikos Viazis, Livia Biancone, Eugeni Domenech, Catherine Reenears, Laurent Peyrin-Biroulet, Laurent Beaugerie, Johan Burisch on behalf of the I-CARE collaborator group
Authorship Rules
Authorship Rules previously voted
General Architecture (Transposed from CESAME)
- Author(A)1, A2, (+/- A3, A4 when additional external expertise is needed) ;
- 6 authors from the SC (not already at a better position in the byline)
- Consecutive blocks of 6 by alphabetic order when the first draft of each article is finalized
- Required committment for reviewing the draft and proposing when necessary alternative rephrasing
- Rotation of the 4 physicians of the Executive Committee (EC)
- Last author
- for the I-CARE Study Group:
- i.e. 13 to 15 authors
- Author (A)1, A2, (+/- A3, A4) and last author = Executive scientific team of the project
Authorship Rules final modalities
- 1 author per participating country and each country designates its representative
- Order of signature: decreasing number of included patients
- 15 authors in the middlle of the list of byline authors
1.Lymphoma in IBD / 2.Colorectal cancer and IBD treatments/ 3.Severe infection in IBD
4.Impact of biologics based strategies on the natural history of IBD and their potential for disease modification
- Rotation of 6 Nat Coord per major paper
- Order of country signature: decreasing number of included patients
What about a fifth ‘major’ paper on « All Cancers », which would allow each country to sign two times in the byline authors (6 x 5 = 30 = 2 x 15)?
- Same rules than major papers
- Proposed name: « The I-CARE collaborator group »
- Designation: First name Last name, hospital, university affiliation, city and country
Example: Laurent Beaugerie, Saint-Antoine Hospital, Sorbonne University, Paris France
- Organized by heading :
"National Coordinator", "Investigators Contributors", "Methodologists", "Coding Group", "Getaid Contributors", "Patients interaction contributors = SANOIA" , "Study Coordinators" etc.